171 related articles for article (PubMed ID: 15645003)
21. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
22. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
23. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
25. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898
[TBL] [Abstract][Full Text] [Related]
26. Atazanavir.
Orrick JJ; Steinhart CR
Ann Pharmacother; 2004 Oct; 38(10):1664-74. PubMed ID: 15353575
[TBL] [Abstract][Full Text] [Related]
27. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
28. Atazanavir: a review of its use in the management of HIV-1 infection.
Croom KF; Dhillon S; Keam SJ
Drugs; 2009 May; 69(8):1107-40. PubMed ID: 19496633
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
[TBL] [Abstract][Full Text] [Related]
31. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
[TBL] [Abstract][Full Text] [Related]
32. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
[TBL] [Abstract][Full Text] [Related]
34. Atazanavir: simplicity and convenience in different scenarios.
Pérez-Elías MJ
Expert Opin Pharmacother; 2007 Apr; 8(5):689-700. PubMed ID: 17376023
[TBL] [Abstract][Full Text] [Related]
35. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
[TBL] [Abstract][Full Text] [Related]
36. Atazanavir.
Goldsmith DR; Perry CM
Drugs; 2003; 63(16):1679-93; discussion 1694-5. PubMed ID: 12904086
[TBL] [Abstract][Full Text] [Related]
37. First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better.
Llibre JM
AIDS Rev; 2009; 11(4):215-22. PubMed ID: 19940948
[TBL] [Abstract][Full Text] [Related]
38. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
[TBL] [Abstract][Full Text] [Related]
39. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
40. Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.
Choi H; Jeong SJ; Lee HS; Chin BS; Choi SH; Han SH; Kim MS; Kim CO; Choi JY; Song YG; Kim JM
J Korean Med Sci; 2008 Aug; 23(4):737-9. PubMed ID: 18756069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
